Abstract: An operation method for an instant messenger server is provided. The method includes generating a schedule which depends on an account of a host in response to a schedule generation request of the host, determining invitees based on at least one of a chat room list and a friend list of the account of the host, synchronizing schedules which depend on accounts of users who participate in the schedule, based on whether at least one guest included in the invitees participates, and providing a notification of the schedule to at least one of the users who participate in the schedule, through a user interface (UI) of a chat room provided through the instant messaging service.

Abstract: The present specification relates to a heterocyclic compound represented by Chemical Formula 1, and an organic light emitting device comprising the same.

Abstract: Various embodiments disclosed herein relates to a fingerprint recognition package and, according to one embodiment, the fingerprint recognition package may comprise: a circuit board; an image sensor die attached and electrically connected to the circuit board; a light-shielding member applied to the circuit board; and an adhesive member attached to one side of the light-shielding member. Various other embodiments are also possible.

Abstract: An operation method for an instant messenger server is provided. The method includes generating a schedule which depends on an account of a host in response to a schedule generation request of the host, determining invitees based on at least one of a chat room list and a friend list of the account of the host, synchronizing schedules which depend on accounts of users who participate in the schedule, based on whether at least one guest included in the invitees participates, and providing a notification of the schedule to at least one of the users who participate in the schedule, through a user interface (UI) of a chat room provided through the instant messaging service.

Abstract: The present invention relates to a pharmaceutical composition containing mitochondria and, more specifically, to a pharmaceutical composition for preventing or treating muscle diseases or ischemic diseases, containing mitochondria as active ingredients. The pharmaceutical composition of the present invention contains heterologous mitochondria or cells comprising heterologous mitochondria, thereby enabling the mitochondrial activity of cells to which the same is administered to improve. Therefore, the pharmaceutical composition according to the present invention can be useful in the fundamental prevention or treatment of muscle diseases or ischemic diseases, which occur in relationship with the deterioration of mitochondrial function.

Abstract: The present specification relates to a novel hetero-cyclic compound and an organic light emitting device using the same.

Abstract: A method is provided for manufacturing a printed circuit board assembly. A method includes applying a liquefied radiant-heat material on a heating component mounted on the printed circuit board; mounting a shield unit on the printed circuit board in contact with the liquefied radiant-heat material; and simultaneously curing the liquefied radiant-heat material and bonding the shield unit.

Abstract: A method is provided for manufacturing a printed circuit board assembly. A method includes applying a liquefied radiant-heat material on a heating component mounted on the printed circuit board; mounting a shield unit on the printed circuit board in contact with the liquefied radiant-heat material; and simultaneously curing the liquefied radiant-heat material and bonding the shield unit.

Abstract: The present application provides a hetero-cyclic compound which may significantly improve the service life, efficiency, electrochemical stability, and thermal stability of an organic light emitting device, and an organic light emitting device in which the hetero-cyclic compound is contained in an organic compound layer.

Abstract: The present specification relates to a novel hetero-cyclic compound and an organic light emitting device using the same.

Abstract: Disclosed are a heterocyclic compound and an organic light emitting device including the same.

Abstract: The present invention relates to beta-glucosidase that is mutated to have enhanced activity, and a method for producing bioethanol using the same. More particularly, the present invention relates to a polynucleotide encoding beta-glucosidase that is mutated to have enhanced activity, beta-glucosidase expressed from the polynucleotide, an expression vector including the polynucleotide, a transformant that is transformed with the expression vector, a method for producing the mutated beta-glucosidase using the transformant, and a method for producing bioethanol using the transformant. The mutant beta-glucosidase of the present invention increases production of glucose much more than the conventional beta-glucosidase, and thus it can be widely used for economic production of bioethanol.

Abstract: A fault diagnosis method of an exhaust gas post-processing system may include a detection step detecting any one or more of an operating state of a lean NOx trap or a state of an urea tank, a determination step determining whether the state of the lean NOx trap or the urea tank detected at the detection step satisfies a corresponding condition to block monitoring of a purification efficiency of the exhaust gas post-processing system, and a blocking step blocking the monitoring of the purification efficiency of the exhaust gas post-processing system when the state of the lean NOx trap or the urea tank at the determination step satisfies the corresponding condition to block the monitoring of the purification efficiency of the exhaust gas post-processing system.

Abstract: Disclosed are a heterocyclic compound and an organic light emitting device including the same.

Abstract: A fault diagnosis method of an exhaust gas post-processing system may include a detection step detecting any one or more of an operating state of a lean NOx trap or a state of an urea tank, a determination step determining whether the state of the lean NOx trap or the urea tank detected at the detection step satisfies a corresponding condition to block monitoring of a purification efficiency of the exhaust gas post-processing system, and a blocking step blocking the monitoring of the purification efficiency of the exhaust gas post-processing system when the state of the lean NOx trap or the urea tank at the determination step satisfies the corresponding condition to block the monitoring of the purification efficiency of the exhaust gas post-processing system.

Abstract: A method is provided for manufacturing a printed circuit board assembly. A method includes applying a liquefied radiant-heat material on a heating component mounted on the printed circuit board; mounting a shield unit on the printed circuit board in contact with the liquefied radiant-heat material; and simultaneously curing the liquefied radiant-heat material and bonding the shield unit.

Abstract: The present invention relates to beta-glucosidase that is mutated to have enhanced activity, and a method for producing bioethanol using the same. More particularly, the present invention relates to a polynucleotide encoding beta-glucosidase that is mutated to have enhanced activity, beta-glucosidase expressed from the polynucleotide, an expression vector including the polynucleotide, a transformant that is transformed with the expression vector, a method for producing the mutated beta-glucosidase using the transformant, and a method for producing bioethanol using the transformant. The mutant beta-glucosidase of the present invention increases production of glucose much more than the conventional beta-glucosidase, and thus it can be widely used for economic production of bioethanol.

Abstract: The present invention relates to a method for producing hEGF (human epidermal growth factor) which has the same activity as the wild form, in high concentration and with a high degree of purity. More specifically, the invention relates to an hEGF expression vector comprising a nucleic acid sequence coding for the polypeptide of sequence number 14; a host cell in which the expression vector has been genetically transformed; and a method for producing hEGF, comprising a step in which the expression vector is created and is genetically transformed in yeast from which the KEX1 gene is lacking. Using the method of the present invention, it is possible to produce a large volume of human derived EGF which has the same size and activity as human derived EGF, and this EGF can be used in various ways such as in medicine and cosmetics.

Abstract: The present invention relates to a composition comprising an extract of Pseudolysimachion genus plant, and the catalpol derivatives isolated therefrom having anti-inflammatory, anti-allergic and anti-asthmatic activity. The extract of Pseudolysimachion genus plant and the catalpol derivatives isolated therefrom shows potent suppressing effect on elevated IgE, IL-4 and IL-13 levels and eosinophilia in the plasma and BALF, and mucus overproduction in the lung tissues in an OVA-induced asthmatic mouse model. Therefore, it can be used as the therapeutics or functional health food for treating and preventing inflammatory, allergic and asthmatic disease.

Abstract: The present invention relates to a cosmetic composition which mimics the extracellular matrix to stimulate the regeneration of skin cells, and more particularly to a cosmetic composition which contains active ingredients consisting of low-molecular-weight materials, which easily permeate through the skin, at a composition ratio similar to that in the extracellular matrix. The cosmetic composition stimulates the repair of the skin to maintain homeostasis and is effective for the regeneration of skin cells.